PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1)
play a crucial role in regulating the immune system and preventing autoimmunity. Cancer …

Background. Innovative drugs targeting the PD1/PD-L1 axis have opened promising
scenarios in modern cancer therapy. Plenty of assays and scoring systems have been …

Background The tumor immune microenvironment (TIME) phenotypes have been reported
to mainly impact the efficacy of immunotherapy. Given the increasing use of immunotherapy …

Simple Summary The cancer-immunity cycle is characterized by various stimulatory and
inhibitory factors, which together regulate the immune response and halt the extreme …

Background Clinical studies have shown that the efficacy of programmed cell death receptor-
1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much …

Immunohistochemical assessment with combined positive score (CPS) of programmed
death-ligand 1 (PD-L1) is the prerequisite for administration of checkpoint inhibitor therapy …

One of the goals of pathology is to standardize laboratory practices to increase the precision
and effectiveness of diagnostic testing, which will ultimately enhance patient care and …

Tumors meet their energy, biosynthesis, and redox demands through metabolic
reprogramming. This metabolic abnormality results in elevated levels of metabolites …

The Schlafen (SLFN) gene family plays an important role in immune cell differentiation and
immune regulation. Previous studies have found that the increased SLFN5 expression in …

Opinion statement Increasing understanding of the complex interaction between leukemic
and immune cells, which is responsible for tumor progression and immune evasion, has …